Suppr超能文献

蛋白激酶Cθ激活环自磷酸化及激酶结构域催化机制的表征

Characterization of protein kinase C theta activation loop autophosphorylation and the kinase domain catalytic mechanism.

作者信息

Czerwinski Robert, Aulabaugh Ann, Greco Rita M, Olland Stephane, Malakian Karl, Wolfrom Scott, Lin Laura, Kriz Ron, Stahl Mark, Huang Ying, Liu Lin, Chaudhary Divya

机构信息

Department of Chemical and Screening Sciences, Wyeth Research, 87 Cambridge Park Drive, Cambridge, Massachusetts 02140, USA.

出版信息

Biochemistry. 2005 Jul 19;44(28):9563-73. doi: 10.1021/bi050608q.

Abstract

Protein kinase C theta (PKCtheta), a member of the Ca(2+)-independent novel subfamily of PKCs, is required for T-cell receptor (TCR) signaling and IL2 production. PKCtheta-deficient mice have impaired Th2 responses in a murine ova-induced asthma model, while Th1 responses are normal. As an essential component of the TCR signaling complex, PKCtheta is a unique T-cell therapeutic target in the specific treatment of T-cell-mediated diseases. We report here the PKCtheta autophosphorylation characteristics and elucidation of the catalytic mechanism of the PKCtheta kinase domain using steady-state kinetics. Key phosphorylated residues of the active PKCtheta kinase domain expressed in Escherichia coli were characterized, and mutational analysis of the kinase domain was performed to establish the autophosphorylation and kinase activity relationships. Initial velocity, product inhibition, and dead-end inhibition studies provided assignments of the kinetic mechanism of PCKtheta(362)(-)(706) as ordered, wherein ATP binds kinase first and ADP is released last. Effects of solvent viscosity and ATPgammaS on PKCtheta catalysis demonstrated product release is partially rate limiting. Our studies provide important mechanistic insights into kinase activity and phosphorylation-mediated regulation of the novel PKC isoform, PKCtheta. These results should aid the design and discovery of PKCtheta antagonists as therapeutics for modulating T-cell-mediated immune and respiratory diseases.

摘要

蛋白激酶Cθ(PKCθ)是蛋白激酶C中不依赖钙离子的新型亚家族成员,是T细胞受体(TCR)信号传导和白细胞介素2产生所必需的。在小鼠卵清蛋白诱导的哮喘模型中,PKCθ缺陷小鼠的Th2反应受损,而Th1反应正常。作为TCR信号复合物的重要组成部分,PKCθ是T细胞介导疾病特异性治疗中独特的T细胞治疗靶点。我们在此报告PKCθ的自磷酸化特征,并利用稳态动力学阐明PKCθ激酶结构域的催化机制。对在大肠杆菌中表达的活性PKCθ激酶结构域的关键磷酸化残基进行了表征,并对激酶结构域进行了突变分析,以建立自磷酸化与激酶活性的关系。初始速度、产物抑制和终产物抑制研究确定了PCKθ(362)(-)(706)的动力学机制为有序机制,即ATP先与激酶结合,ADP最后释放。溶剂粘度和ATPγS对PKCθ催化作用的影响表明产物释放是部分限速步骤。我们的研究为新型PKC亚型PKCθ的激酶活性和磷酸化介导的调节提供了重要的机制见解。这些结果应有助于设计和发现PKCθ拮抗剂,作为调节T细胞介导的免疫和呼吸系统疾病的治疗药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验